Hormone-receptor positive breast cancer: highlights from the 39TH San Antonio Breast Cancer Symposium.

about

Hormone-receptor positive breast cancer: highlights from the 39TH San Antonio Breast Cancer Symposium.

Item

http://www.wikidata.org/entity/Q38798302

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Hormone-receptor positive brea ...... tonio Breast Cancer Symposium.

@en

type

Item

label

Hormone-receptor positive brea ...... tonio Breast Cancer Symposium.

@en

prefLabel

Hormone-receptor positive brea ...... tonio Breast Cancer Symposium.

@en

P1476

Hormone-receptor positive brea ...... tonio Breast Cancer Symposium.

@en

P2093

Filippo Montemurro

http://www.w3.org/2001/XMLSchema#string

Giorgia Zucchini

http://www.w3.org/2001/XMLSchema#string

P2860

Comprehensive molecular portraits of human breast tumours

Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline

Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer

Efficacy and safety of palbociclib in combination with letrozole as first-line treatment of ER-positive, HER2-negative, advanced breast cancer: expanded analyses of subgroups from the randomized pivotal trial PALOMA-1/TRIO-18.

Biological determinants of endocrine resistance in breast cancer.

Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update on Ovarian Suppression.

Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind

Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer.

Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial.

P304

853-855

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/14656566.2017.1328500

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-05-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28481697

http://www.w3.org/2001/XMLSchema#string